NO150361C - Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater

Info

Publication number
NO150361C
NO150361C NO781786A NO781786A NO150361C NO 150361 C NO150361 C NO 150361C NO 781786 A NO781786 A NO 781786A NO 781786 A NO781786 A NO 781786A NO 150361 C NO150361 C NO 150361C
Authority
NO
Norway
Prior art keywords
tetrazol
pyrido
pyrimidin
derivatives
preparation
Prior art date
Application number
NO781786A
Other languages
English (en)
Norwegian (no)
Other versions
NO781786L (no
NO150361B (no
Inventor
Peter Frederick Juby
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NO781786L publication Critical patent/NO781786L/no
Publication of NO150361B publication Critical patent/NO150361B/no
Publication of NO150361C publication Critical patent/NO150361C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO781786A 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater NO150361C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (3)

Publication Number Publication Date
NO781786L NO781786L (no) 1978-11-28
NO150361B NO150361B (no) 1984-06-25
NO150361C true NO150361C (no) 1984-10-03

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO781786A NO150361C (no) 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater

Country Status (26)

Country Link
US (1) US4122274A (it)
JP (1) JPS6050197B2 (it)
AT (1) AT365187B (it)
AU (1) AU521211B2 (it)
BE (1) BE867295A (it)
CA (1) CA1098520A (it)
CH (1) CH642656A5 (it)
CY (1) CY1218A (it)
DE (1) DE2822544A1 (it)
DK (1) DK160279C (it)
FI (1) FI64594C (it)
FR (1) FR2401159A1 (it)
GB (1) GB1596476A (it)
GR (1) GR71887B (it)
HK (1) HK25884A (it)
IE (1) IE46849B1 (it)
IT (1) IT1105040B (it)
KE (1) KE3357A (it)
LU (1) LU79694A1 (it)
MY (1) MY8500305A (it)
NL (1) NL190702C (it)
NO (1) NO150361C (it)
SE (1) SE437830B (it)
SG (1) SG73383G (it)
YU (2) YU42163B (it)
ZA (1) ZA782816B (it)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
CA1283411C (en) * 1985-09-25 1991-04-23 Masami Doteuchi 9-(substituted thio)-4h-pyrido[1,2-a]-pyrimidin-4-one derivatives
JPS63183581A (ja) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd ピリド〔１，２−ａ〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬
JPS62242682A (ja) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd 新規なピリド［１，２―ａ］ピリミジン誘導体及びその製造法
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
WO1989006130A1 (en) * 1987-12-25 1989-07-13 Santen Pharmaceutical Co., Ltd. Antiallergic eye drop
CA2010336C (en) * 1989-02-27 1996-11-19 Atsunori Sano Process for producing pyrido[1,2-a]pyrimidine derivative
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
EP0653209A4 (en) 1992-07-30 1997-03-19 Tokyo Tanabe Co MEDICINAL PRODUCTS FOR INFLAMMATORY COLON DISEASES.
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (ja) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd ９−メチル−３−（１Ｈ−テトラゾール−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンの水性製剤
KR100885007B1 (ko) * 2001-02-26 2009-02-20 미쓰비시 타나베 파마 코퍼레이션 신질환·신부전의 예방 또는 치료를 위한 약학 조성물
ITMI20011764A1 (it) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
JP2010513430A (ja) * 2006-12-18 2010-04-30 カルドズ・アーベー 炎症障害の治療において使用するための新たな併用
CA2673214A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
EP2175845A2 (en) * 2007-07-11 2010-04-21 Cardoz AB New combination for use in the treatment of inflammatory disorders
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
US20110092463A1 (en) * 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
KR20170049645A (ko) * 2009-06-16 2017-05-10 카르도스 아베 페미로라스트의 신규한 결정형
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
JP6092897B2 (ja) * 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
KR102099997B1 (ko) 2012-03-01 2020-04-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2016063085A1 (en) 2014-10-23 2016-04-28 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
JP6749343B2 (ja) * 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
PL3386511T3 (pl) 2015-12-10 2021-11-08 Ptc Therapeutics, Inc. Sposoby leczenia choroby huntingtona
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
FI3814357T3 (fi) 2018-06-27 2024-07-26 Ptc Therapeutics Inc Heterosykliset ja heteroaryliyhdisteet huntingtonin taudin hoitoon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
AT294107B (de) * 1966-11-02 1971-11-10 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von neuen Homopyrimidazol-Derivaten sowie von deren Salzen
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
CY1218A (en) 1984-04-06
FR2401159B1 (it) 1983-05-20
BE867295A (fr) 1978-11-20
CA1098520A (en) 1981-03-31
NL190702B (nl) 1994-02-01
IE46849B1 (en) 1983-10-05
IE781036L (en) 1978-11-25
YU42163B (en) 1988-06-30
DK160279C (da) 1991-07-22
JPS6050197B2 (ja) 1985-11-07
NO781786L (no) 1978-11-28
FI781614A (fi) 1978-11-26
GB1596476A (en) 1981-08-26
NL7805534A (nl) 1978-11-28
YU123678A (en) 1983-02-28
DK160279B (da) 1991-02-18
SE437830B (sv) 1985-03-18
YU233082A (en) 1988-08-31
DK228878A (da) 1978-11-26
SE7805954L (sv) 1978-11-26
IT1105040B (it) 1985-10-28
NO150361B (no) 1984-06-25
LU79694A1 (fr) 1979-02-02
YU44212B (en) 1990-04-30
MY8500305A (en) 1985-12-31
KE3357A (en) 1984-02-03
ZA782816B (en) 1979-05-30
SG73383G (en) 1984-08-03
JPS5436294A (en) 1979-03-16
FR2401159A1 (fr) 1979-03-23
DE2822544A1 (de) 1978-12-07
AU521211B2 (en) 1982-03-25
CH642656A5 (de) 1984-04-30
HK25884A (en) 1984-03-30
AU3631978A (en) 1979-11-29
US4122274A (en) 1978-10-24
GR71887B (it) 1983-08-04
ATA373278A (de) 1981-05-15
FI64594C (fi) 1983-12-12
AT365187B (de) 1981-12-28
IT7849523A0 (it) 1978-05-24
FI64594B (fi) 1983-08-31
DE2822544C2 (it) 1988-10-27
NL190702C (nl) 1994-07-01

Similar Documents

Publication Publication Date Title
NO150361C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
NO155774C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo-diazepin-derivater.
NO145657C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.
NO148148C (no) Fremgangsmaate til fremstilling av terapeutisk aktive 4-hydroksy-2-pyrrolidinonderivater
NO784211L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO784231L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive benzotiazinderivater
NO156785B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
NO156752B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-(1-piperidinylalkyl)-4hpyrido(1,2-a)pyrimidin-4-0n derivater
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO155055C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-carboxylsyrederivater.
NO143219C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO151287C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)-pyrimidinderivater
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO782756L (no) Fremgangsmaate for fremstilling av terapeutisk aktive antrakinonderivater
NO146865C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 16-dehydro-androstanderivater
NO155665C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,7,7a-tetrahydro-4h-thieno-(3,2-c)-pyridin-2-on-derivater.
NO148644C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive sukkerderivater.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
NO158800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenderivater.
NO156167C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinon-derivater.
NO151660C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater.
NO150158C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6,7-dimetoksyquinazolinderivater
NO164095C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av 3-(3-substituerte-amino-2-hydroksypropoksy)-4-substituerte-1,2,5-tiadiazolderivater.